Ajinomoto Co., Ltd.

Other

Japanese Foundation for Cancer Research

Kazuo Sugamura

Morishita Pharmaceuticals Co. Ltd.

Junji Hamuro

Toshiro Shimamura

Manabu Suzuki

Nobukazu Kashima

Toshikazu Takeshita

Hiroshi Matsui

Tadatsugu Taniguchi

Noriyuki Sato

Haruo Sugano

Masami Muramatsu

Kokichi Kikuchi

Harumi Nakazawa

Masataka Nakamura

Hironobu Asao

Ryota Yoshimoto

Hiroeki Sahara

Toshihiko Torigoe

Yoshimasa Wada

Yukie Murata

Yuka Kanayama

Takahiro Yasojima

Hiromitsu Sahara

Koji Mitsugi

Yasumi Yugari

Tsuyoshi Shiio

Mitsuharu Fujii

Yoshiaki Hanzawa

Shinsuke Taki

Yayoi Yoshinari

Tatsuo Kuoka

Tatsuo Setsuta

Yutaka Iwao

Takashi Yoshihama

A method of suppressing immune responses, comprising administering to a patient in need thereof an effective amount of a composition comprising a substance capable of reducing the content of reductive glutathione in macrophages.

Method of suppressing immune response by reducing intracellular content of glutathione in macrophages and monocytes

A tumor antigen gene is identified by screening a cDNA library derived from a gastric cancer cell line that can induce gastric cancer antigen specific cytotoxic T cell (CTL) by means of hybridization and PCR utilizing an amino acid sequence of peptide fragment of a known gastric cancer antigen protein, introducing a selected cDNA clone into a cell of gastric cancer cell line that cannot induce gastric cancer antigen specific CTL so that the clone should be expressed in the cell, and selecting a transgenic cell that has acquired the ability to induce CTL. According to the present invention, there are provided a protein capable of inducing immune response against human gastric cancer, DNA encoding the protein, as well as vaccine for treatment and prevention of human gastric cancer, and agent for treatment and prevention of human gastric cancer.

Human gastric cancer antigen gene and gastric cancer antigen protein

A peptide that induces CTL against human gastric cancer cells is provided. A peptide having a specific amino-acid sequence and induces cytotoxic T cells that targets gastric cancer cells may be used as an agent for preventing or treating gastric cancer.

Peptide capable of inducing immune response to human gastric cancer and agent for preventing or treating human gastric cancer, containing the peptide

Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes

The present invention relates to an IL-2 receptor .gamma. chain molecule, a DNA-sequence encoding the IL-2 receptor .gamma. chain molecule, a vector possessing said DNA-sequence, a cell transformed with said vector, a method for the production of an IL-2 receptor .gamma. chain molecule by culturing of said cell, an immune response regulatory agent comprising an IL-2 receptor .gamma. chain molecule and an antibody to an IL-2 receptor .gamma. chain molecule.

Human IL-2 receptor .gamma.-chain molecule antibody

The present invention relates to (1) polypeptide capable of binding to .beta. chain of IL-2 receptor and having the inhibitory activity of the binding between IL-2 and .beta. chain of IL-2 receptor, and (2) the process of producing the polypeptide, especially in E. coli as a host. THe polypeptide according to the present invention and the pharmaceutical composition containing the polypeptide are useful to prevent rejection of organ transplantation and also to cure autoimmune diseases.

Polypeptides capable of binding to heavy chains of IL-2 receptors

A polypeptide which specifically binds to the .gamma.-chain of the human interleukin-2 receptor and selectively inhibits the binding of the .gamma.-chain of human interleukin-2 receptor to the .beta.-chain of the same is provided. The polypeptide has an activity of blocking the human interleukin-2 response. Also provided are an immunosuppressant containing the polypeptide, a DNA gene coding for the polypeptide, a recombinant DNA having the gene, a transformant having the recombinant DNA, and a method for producing the intended polypeptide by incubating the transformant. The novel polypeptide can be used independently, or with substances capable of inhibiting the binding of interleukin-2 to the interleukin-2 receptor, as a medicine for preventing the rejection of grafts after transplantation and also for curing inflammatory diseases such as allergic diseases and autoimmune diseases.

.gamma.-chain humaninterleukin-2 receptor polypeptide and method of

Peptide capable of inducing immune response to human gastric cancer and

The invention provides a method for detecting (1) leukemia, (2) cancer, (3) autoimmune disorder, (4) inflammatory disorder, (5) allergic disorder or (6) viral infection, characterized by measuring soluble, human interleukin-2 receptor .gamma.-chain molecules existing in a human body fluid by an immunochemical method using an antibody/antibodies specifically reacting with human interleukin-2 receptor .gamma.-chain molecule, and a reagent for the detection.

Method and reagent detecting human disorders

A gene coded for a polypeptide which possesses interleukin-2 is isolated, and connected with a vector DNA which is capable of replicating in a procaryotic or eucaryotic cell at a position downstream of a promoter gene in the vector obtaining a recombinant DNA, with which the cell is trans-formed to produce interleukin-2.

Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the

The present invention relates to an IL-2 receptor .gamma. chain molecule, a DNA-sequence encoding the IL-2 receptor .gamma. chain molecule, a vector possessing said DNA-sequence, a cell transformed with said vector, a method for the production of an IL-2 receptor .gamma. chain molecule by culturing of said cell, an immune response regulatory agent comprising an Il-2 receptor .gamma. chain molecule and an antibody to an IL-2 receptor .gamma. chain molecule. Both the Il-2 receptor .gamma. chain molecule and the antibody to the IL-2 receptor .gamma. chain molecule are very useful immune response regulatory agents.

Human IL-2 receptor .gamma. chain molecule

Recombinant human Interleukin-2 (IL-2) polypeptides are provided. The polypeptides are produced by expression of suitable nucleic acid molecules in transformed host cells such as E. coli.

Unglycosylated human interleukin-2 polypeptides

Peptides which inhibit the binding of human IL-6 to human IL-6 receptor are useful as a treatment for diseases induced or aggravated by IL-6. DNA fragments, vectors, transformants, and methods useful for preparing such peptides are described.

Immunosuppressant

A gene coded for a polypeptide which possesses interleukin-2 is isolated, and connected with a vector DNA which is capable of replicating in a procaryotic or eucaryotic cell at a position downstream of a promoter gene in the vector obtaining a recombinant DNA, with which the cell is transformed to produce interleukin-2.

Growing community of inventors

Kawasaki, Japan

Junji Hamuro